|
Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.
|
 |
|
Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.
|
|
|
Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.
|
|
|
The British drugmaker shelved a separate £450m ($612m) investment in a vaccine manufacturing plant in northern England, earlier this year.
|
|
|
FDA chief Martin Makary said the agency will now ‘proactively monitor’ pharma companies for advertising law breaches.
|
|
